

Course Detail

MMWR Weekly – August 12, 2011

Course Number: SS1747-08122011

CE Origination Date: August 12, 2011

CE Expiration Date: September 26, 2011

Content Experts/Prepares

HIV Prevalence Among Heterosexuals in Urban Areas with High AIDS Prevalence — 24 Cities, United States, 2006–2007

Paul H. Denning, MD, MPH, Medical Officer, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Elizabeth A. DiNenno, PhD, MA, Behavioral Scientist, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Ryan E. Wiegand, MS, Mathematical Statistician, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Human Rabies from Exposure to a Vampire Bat in Mexico — Louisiana, 2010

Gary Balsamo, DVM, MPH, State Public Health Veterinarian, Louisiana Department of Health and Hospitals

Fernando V. Pino, DVM, National Zoonosis Program, Mexico Secretariat of Health

Bret W Peterson, MD, MPH, EIS Officer, CDC

Raoult C. Ratard, MD, MPH, State Epidemiologist, Louisiana Department of Health and Hospitals

Charles E. Rupprecht, VMD, PhD, Chief, Rabies Program, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases

Armand G. Sprecher, MD, EIS Officer, CDC

Deepu R. Thoppil, MD, Louisiana State University Hospital

Monika Thoppil, MD, Louisiana State University Hospital

Progress Toward Poliomyelitis Eradication — Nigeria, January 2010–June 2011

Margaret Hercules, MPH, BSN, Public Health Advisor, Division of Viral Diseases and Global Immunization Division, National Center for Immunization and Respiratory Diseases, CDC

Steven G Wassilak, MD, Epidemiologist, Global Immunization Division, , National Center for Immunization and Respiratory Diseases, CDC

Disclosure

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: N/A